In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Dermira (DERM), with a price target of $25. The company’s shares closed yesterday at $10.61.
Chen observed:
“DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 5.7% and a 37.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dermira with a $22.14 average price target, a 108.7% upside from current levels. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $22 price target.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $64.83 million. In comparison, last year the company had a GAAP net loss of $59.25 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.
